Oncolytics Biotech

Oncolytics is developing pelareorep, an IV delivered I-O agent, which introduces double-stranded RNA into cancer cells.
Contact company:

[Oncolytics Biotech @Oncolytics]

We have appointed Steve Glover to the Oncolytics Board and promoted John McAdory to Chief Operating Officer. Both will play crucial roles as we position #pelareorep as an immunotherapy backbone for #GastrointestinalCancer patients. Read the PR here: https://t.co/vExkHJcBLA

[Oncolytics Biotech @Oncolytics]

As a result of positive anti-tumor activity for #pelareorep and a #RAS inhibitor, Oncolytics plans to explore combinations with multiple #KRAS and RAS inhibitors in RAS-mutated tumor models, supporting our work in #ColorectalCancer and #PancreaticCancer
https://t.co/dpVASjU3wB

[Oncolytics Biotech @Oncolytics]

⏳ 2 days to go
Register now to join @endpts for a live discussion on systemic viral immunotherapy as a backbone strategy in GI oncology, with insights on CRC & SCAC study design and regulatory pathways.
📅 May 28 | 🕚 11:30–12:30 ET https://t.co/ITOaxaVMbP

[Oncolytics Biotech @Oncolytics]

At #ASCO26, we’ll present translational data showing pelareorep, an investigational IV immunotherapy, is associated with expansion of mutant KRAS-specific‑specific T‑cell clones in blood, supporting its relevance in RAS‑driven GI cancers. https://t.co/4Y2nssaw1w

[Oncolytics Biotech @Oncolytics]

What you'll learn during our @endpts webinar:

🔹 Systemic viral immunotherapy as a GI backbone
🔹 Registrational study design in CRC & SCAC
🔹 How regulatory clarity enables efficient development & partnering

👉 Register now: https://t.co/ITOaxaWk1n

[Oncolytics Biotech @Oncolytics]

Jared will be presenting the vision for #pelareorep as an enhancement therapy for GI tumors at the #JefferiesHealthcare Conference on June 4 at 12:50pm ET. He will discuss the ongoing #ColorectalCancer trial, recent FDA alignment, and more. For a 1x1, contact your @Jefferies rep.

[Oncolytics Biotech @Oncolytics]

At #ASGCT2026 we discussed how TLR3 is activated by #pelareorep. TLR3 activates innate immune pathways that lead to the formation of tertiary lymphoid structures, which have been shown to improve patient responses to immunotherapies. Thanks to @ASGCTherapy for hosting.

[Oncolytics Biotech @Oncolytics]

IO progress depends on deeper biology and translation. Our CEO Jared Kelly joined @FierceBiotech Week to explore why many programs fail—and how biologically differentiated, systemically delivered platforms can better organize immune responses.

[Oncolytics Biotech @Oncolytics]

How do you reprogram the tumor microenvironment? 🧬
Our Richard Trauger, Executive Director of Translational Science, shares insights on pelareorep, TLR3 activation, and immune remodeling at @ASGCTherapy. Don’t miss this session. https://t.co/2bb16ZxOfB

[Oncolytics Biotech @Oncolytics]

Hear from leaders advancing next‑generation GI oncology. Register to join @endpts for a live discussion on systemic viral immunotherapy as a backbone strategy in GI cancers, including CRC and SCAC.
📅 May 28 | 🕚 11:30–12:30 ET
👉 Register: https://t.co/ITOaxaVMbP

[Oncolytics Biotech @Oncolytics]

Congratulations to our CEO, Jared Kelly, on his nomination as one of In Vivo's 2026 Rising Leaders. You can read more about Jared and the full list of nominees by clicking the following @Citeline link: https://t.co/t3SpasRyAV

[Oncolytics Biotech @Oncolytics]

Join us and our special guests on May 28 for a live @endpts webinar exploring what’s next in systemically delivered, immune-activating therapies, with a spotlight on upcoming studies in areas of significant unmet need in GI oncology. https://t.co/ITOaxaVMbP

[Oncolytics Biotech @Oncolytics]

Additional analysis from the REO 022 CRC study shows a median duration of response of 19.5 months compared to 4-6 months in historical trials. This gives hope to patients in the 2L setting and could support a path to accelerated approval for #pelareorep: https://t.co/esWDmlkjma

[Zacks SCR @ZacksSmallCap]

$ONCY @Oncolytics is building a GI oncology pipeline with a clear regulatory strategy and compelling early data. Senior Analyst @DavidBautz sat down with CEO Jared Kelly for the full picture. https://t.co/ScTc09awBI

#OncolyticsBiotech #Biotech #Oncology #SmallCap

[Oncolytics Biotech @Oncolytics]

From #AACR26 to #IOVC, our leaders are engaging with the global cancer research community and sharing new data that continue to support pelareorep’s potential as a systemic immune‑priming backbone in GI cancers.

[Oncolytics Biotech @Oncolytics]

A consistent theme is emerging across our abstracts at IOVC: immune priming works when it’s coordinated and repeatable. From AACR to IOVC, the immune‑priming conversation continues to build, including in hard‑to‑treat GI cancers. Learn more: https://t.co/5jl5WL0PSz

[Oncolytics Biotech @Oncolytics]

After a Type C meeting, we’ve aligned with the FDA on a pivotal, randomized SCAC study for pelareorep. The plan defines a clear, single-study framework designed to support accelerated and full approval, built for rigor in a GI cancer with high unmet need. https://t.co/PYYzNgCdIX

[Oncolytics Biotech @Oncolytics]

We've scheduled a Type C meeting with the FDA to discuss a potential registrational pathway for pelareorep—an investigational immunotherapy—in second‑line and later squamous cell anal carcinoma (SCAC), a setting with limited approved options.

Read more: 👉https://t.co/rXymetCzsG

[Oncolytics Biotech @Oncolytics]

We’ve completed our move to a U.S. corporate domicile, aligning our structure with U.S.-based operations, leadership, investors, and capital markets. Simplified regulation, greater efficiency, and stronger access to U.S. financing as we advance pelareorep. https://t.co/iRdJxkWMrt

[Oncolytics Biotech @Oncolytics]

GI tumors are often “cold” and resistant to immunotherapy, limiting patient benefit.

We’re working to change the biology, and our new #AACR2026 data from AWARE‑1 and GOBLET show reproducible immune activation across pancreatic and breast cancer.